Materialise NV
As of Oct 22, 2026, Materialise NV is in Stage 2, the uptrend phase, now in week 20 (since Jun 8, 2026). It closed at $8.53, 2.5% below its 52-week high and above its 200-day average, which is rising.
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 81 in Software - Application · #1 of 242 in Information Technology
Is MTLS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MTLS among Software - Application24th of 221 by relative strength
All 221 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | RNG | Stage 2 · wk 13 | 97 | +0.2% |
| 2 | DHX | Stage 2 · wk 29 | 97 | +3.5% |
| 3 | FSLY | Stage 2 · wk 11 | 97 | −24.3% |
| 4 | PUBM | Stage 2 · wk 24 | 95 | −1.6% |
| 5 | FROG | Stage 2 · wk 21 | 94 | +1.7% |
| 6 | MITK | Stage 3 · wk 5 | 93 | +1.0% |
| 7 | RSKD | Stage 2 · wk 19 | 93 | +24.9% |
| 8 | OOMA | Stage 3 · wk 1 | 92 | −10.7% |
| …24 | MTLS | Stage 2 · wk 20 | 81 | +6.8% |
Materialise NV: quick answers
What stage is Materialise NV in?
As of Oct 22, 2026, Materialise NV (MTLS) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 8, 2026 and is in week 20. What the four stages mean
Is Materialise NV in an uptrend?
Yes. Materialise NV is in a Stage 2 uptrend. It trades 34.9% above its 200-day average, which is rising.
How far is Materialise NV from its 52-week high?
Materialise NV closed at $8.53 on Oct 22, 2026, 2.5% below its 52-week high of $8.75. Its 52-week low is $4.80.
How has Materialise NV performed over the past year?
As of Oct 22, 2026, Materialise NV is up 38.9% over the past year and up 56.5% so far in 2026.
Which sector and industry is Materialise NV in?
Materialise NV is in the Software - Application industry, part of the Information Technology sector.
About this companyInformation Technology· Software - Application
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.